supernu report dilut ep revenu compar street
estim respect manag guid product sale
impli growth rate mid-point rang though
commerci execut stellar bit concern recent prescript
rx volum trend continu believ street estim share
alreadi reflect expect signific long-term growth price-to-earnings
ep estim context compound-annual-growth-rate north put anoth way
loss trokendi xr exclus share reflect signific
expect pipelin either way risk/reward profil current level ideal
reiter neutral rate slightli rais pt owe modest
worri trajectori trokendi xr trokendi xr sale
grew versu versu rx grew
versu respect per im said rx
show quarter-to-d sequenti growth rate less versu
correspond period though versu manag made clear
date see way step edit prior author though
footprint product grow least percentag volum overal
topiram market would shock see dynam start chang
latest color manag note pivot studi
impulsive-aggress ia associ adhd first phase trial
enrol second studi enrol expect enrol
continu continu expect announc top-lin result next
year notabl plan initi third pivot trial adolesc ia
popul later year expect studi significantli impact
file timelin said dynam still fluid given compani
still discuss studi fda clear data need
roll initi nda ad road
phase data expect recal run number
pivot studi evalu norepinephrin ne reuptak inhibitor nre
children adhd believ main risk surround program commerci
given view clean efficaci toler data phase iib studi
given class well-establish set strattera said
avail strattera gener eventu avail sunovion dasotralin
ne/dopamin reuptak inhibitor potenti later year give us paus
disc
debt total capit
commerci risk epilepsi product clinic risk adhd pipelin
supernu focus treatment disord
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
actual versu pjc consensu estim
consensu estim
compani report factset pjc estim
compani report pjc estim
page
million except per shareactualpjc estimatesrevenuetrokendi xr mr xr mr consensu consensu outstand except per guidanceestimatestot product tax
consensu
compani report factset pjc estim
page
million except per sharecurrentpriorcurrentpriorcurrentpriorrevenuestrokendi xr mr xr mr gener oper incom expens tax provis outstand supernu quarterli annual incom statement
million except ep
sale
sell gener administr
amort intang
incom loss tax
expens product sale
sell gener administr
royalti sale partner product includ payment unit relat fda approv orenitram receipt payment relat royalti stream orenitram
proprietari piper jaffray co februari
current disclosur inform compani found
